Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has issued an announcement.
China Resources Pharmaceutical Group Ltd. has entered into a supplemental framework agreement with its controlling shareholder, China Resources (Holdings) Co. Ltd. (CR Holdings), under which the CR Holdings Group will continue to lease properties and provide property management services, including cleaning and security, to the pharmaceutical group from 1 January 2026 to 31 December 2028. The transactions, conducted on normal commercial terms and priced with reference to market conditions and property characteristics, are classified as continuing connected transactions under Hong Kong’s Listing Rules; because the relevant percentage ratios fall between 0.1% and 5%, they are subject to reporting, announcement and annual review requirements but are exempt from independent shareholders’ approval, ensuring regulatory compliance while securing operational premises and services for the group’s ongoing business needs.
The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. is a Hong Kong–incorporated pharmaceutical company engaged in the manufacture, distribution and retail of pharmaceutical products and related healthcare services, serving hospitals, pharmacies and other healthcare institutions across China.
YTD Price Performance: -17.61%
Average Trading Volume: 14,001,577
Technical Sentiment Signal: Sell
Current Market Cap: HK$28.71B
For a thorough assessment of 3320 stock, go to TipRanks’ Stock Analysis page.